Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
4th Annual Pain Therapeutics Summit
| Type | Conference |
|---|---|
| Language | English |
| Date |
October 4, 2010
to October 5, 2010 |
| Venue |
CHF Conference Center, Chemical Heritage Foundation 314 Chestnut Street Philadelphia, PA 19106 US |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
John Waslif Arrowhead Publishers & Conferences 5412 Irving Avenue South Minneapolis, MN 55419 US 312-244-3703 312-244-3703 john.waslif@paintherapeuticsummit.com |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.
Session titles
Animal Models in Pain Drug Discovery: Friend or Foe? ***
A Whole Genome Approach in Research for Pain and Analgesia ***
Abuse and Diversion of Controlled Substances: Are FDA Mandated REMS the Remedy? ***
Clinical Development Status of Ralfinamide: a Nav 1.7 NCE ***
Critical Compliance and Risk Management Issues for Pain Practitioners: Stepping Stones to Success ***
Challenges to Analgesic Drug Development and the Role of Efficient Proof of Concept Studies ***
Phase III Clinical Success for a Dual Opioid: the Story of MoxDuo, a Morphine/Oxycodone Combination Product ***
Meeting the Challenges Facing Developers of Pain Therapeutics: Safety, REMS and Abuse Liability ***
TrpV1 Antagonists for Pain: “Hot” Target or Not? ***
Development of CG100649, a Tissue-specific Dual Inhibitor of COX-2 and Carbonic Anhydrase, for Treatment of Hip and Knee Osteoarthritis ***
Advancing P2X4 and P2X7 Candidates for Pain Indications ***
Clinical Status of Kappa Agonists for Post-Operative Pain ***
Anti-NGF Clinical Development Program Outcomes: an Update ***
Na+ Channels in Primary Afferent Neurons from Physiology to Pathophysiology ***
What’s Wrong with Animal Models of Pain? ***
Novel Indications for TNF Inhibitors in Pain Management ***